Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

Systemic Effects of Testosterone: Hormonal and Behavioral Mechanisms.

Nikol'skaya KA, Kondashevskaya MV, Serkova VV, Diatropov ME.

Bull Exp Biol Med. 2016 Mar;160(5):622-4. doi: 10.1007/s10517-016-3232-6. Epub 2016 Mar 29.

PMID:
27021106
2.

Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.

Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, Breithardt G, Singer DE, Hankey GJ, Hacke W, Becker RC, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, Califf RM; ROCKET AF Steering Committee & Investigators; ROCKET AF Steering Committee Investigators.

J Am Heart Assoc. 2016 Mar 8;5(3):e002197. doi: 10.1161/JAHA.115.002197.

3.

[HIPPOCAMPUS AS AN ORGANIZER OF RESENT ATTENTION].

Serkova VV, Nikolskaya KA, Eremina LV.

Ross Fiziol Zh Im I M Sechenova. 2015 Jun;101(6):678-88. Russian.

PMID:
26470487
4.

[The Interaction of the Medial Prefrontal Cortex, Ventral Hippocampus and Basolateral Amygdala in the Course of Performance of Conditioned Avoidance Reflex].

Serkov AN, Serkova VV, Maiorov VI.

Zh Vyssh Nerv Deiat Im I P Pavlova. 2015 Mar-Apr;65(2):230-9. Russian.

PMID:
26080601
5.

[Spatial imprinting influence on development of cognitive process in adult animals].

Serkova VV, Nikol'skaia KA.

Ross Fiziol Zh Im I M Sechenova. 2013 Dec;99(12):1366-77. Russian.

PMID:
25464767
6.

Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).

Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, Breithardt G, Singer DE, Becker RC, Hacke W, Paolini JF, Nessel CC, Mahaffey KW, Califf RM, Fox KA; ROCKET AF Steering Committee and Investigators.

Circulation. 2014 Jul 8;130(2):138-46. doi: 10.1161/CIRCULATIONAHA.113.005008. Epub 2014 Jun 3.

7.

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.

Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donnan GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, Singer DE, Wong L, Califf RM, Fox KA, Hacke W; ROCKET AF Steering Committee Investigators.

Lancet Neurol. 2012 Apr;11(4):315-22. doi: 10.1016/S1474-4422(12)70042-X. Epub 2012 Mar 7.

PMID:
22402056
9.

Rivaroxaban in patients with a recent acute coronary syndrome.

Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2–TIMI 51 Investigators.

N Engl J Med. 2012 Jan 5;366(1):9-19. doi: 10.1056/NEJMoa1112277. Epub 2011 Nov 13.

10.

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators.

N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.

11.

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.

Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators.

Lancet. 2010 Sep 11;376(9744):875-85. doi: 10.1016/S0140-6736(10)61198-1. Erratum in: Lancet. 2010 Dec 11;376(9757):1988. Lajnscak, M [corrected to Lainscak, M]; Rabanedo, I Roldan [corrected to Rabadán, I Roldan]; Leva, M [corrected to Ieva, M].

PMID:
20801500
12.

[Quality of life and 24 hour blood pressure profile in patients with hypertension].

Serkova VK, Kuz'minova NV, Alshantti IS.

Lik Sprava. 2009 Jan-Feb;(1-2):49-55. Russian.

PMID:
19953991
13.

Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.

Fox K, Ford I, Steg PG, Tendera M, Ferrari R; BEAUTIFUL Investigators.

Lancet. 2008 Sep 6;372(9641):807-16. doi: 10.1016/S0140-6736(08)61170-8. Epub 2008 Aug 29.

PMID:
18757088
15.

[Effect of antihypertensive therapy on indices for lipid peroxidation and antioxidant system in patients with hypertensive heart].

Serkova VK, Burdeĭnaia LV.

Lik Sprava. 2002 Jul-Sep;(5-6):12-6. Review. Ukrainian.

PMID:
12442509
16.
17.

[Blood lipids, lipid peroxidation and the effect on them of antianginal preparations in ischemic heart disease patients].

Serkova VK, Zhebel' VN, Filenko LV, Savitskaia EA.

Eksp Klin Farmakol. 1998 Mar-Apr;61(2):75-8. Review. Russian.

PMID:
9621182
18.

[Enterosorbents in the treatment of atherosclerosis].

Piskun RP, Pentiuk AA, Serkova VK, Polesia TL, Savitskaia EA.

Eksp Klin Farmakol. 1998 Mar-Apr;61(2):69-74. Review. Russian.

PMID:
9621181
19.

[The possible means for the pharmacological correction of lipid metabolic disorders in atherosclerosis].

Piskun RP, Pentiuk AA, Serkova VK, Polesia TL, Savitskaia EA.

Eksp Klin Farmakol. 1997 Mar-Apr;60(2):78-85. Review. Russian.

PMID:
9206580
20.

[The oxidant and antioxidant systems in patients with stable stenocardia and with a history of small- and large-focus myocardial infarcts].

Tokar' AV, Zhebel' VN, Serkova VK, Litoshenko AIa, Temnaia EV.

Lik Sprava. 1994 Jul-Aug;(7-8):36-40. Russian.

PMID:
7900351

Supplemental Content

Loading ...
Support Center